ArticleMedical oncology (Northwood, London, England)2025
Exploring novel therapeutic strategies: Static Magnetic Fields in combination with doxorubicin induce ROS and apoptosis in acute lymphoblastic leukemia cells.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lymphoblastic leukemia (ALL), primarily affecting children, is a rare malignancy. This study explores the use of alternative therapies such as Static Magnetic Fields (SMF) and Doxorubicin (Dox) as a novel therapeutic strategy for ALL NALM-6 cells. Viability, apoptosis, cell cycle, ROS, and gene expression were assessed using Trypan blue, MTT, flow cytometry, and qRT-PCR. SMF significantly reduced NALM-6 viability and metabolic activity, increased apoptosis and ROS, and altered gene expression related to apoptosis, ROS, cell cycle, and autophagy. Co-treatment with SMF and Dox enhanced these effects compared to single treatments (p ≤ .05), with no cytotoxicity to normal PBMCs or L929 cells. SMF alone or with Dox induces ROS-mediated apoptosis and autophagy inhibition, suggesting a potential complementary therapy, though further research is needed.
Indexed as
Identifiers
41160187What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.